Misonix Exhibits At The 65th Southern Neurosurgical Society Annual Conference And Offers Extensive "Hands-On" BoneScalpel™ and SonaStar® Product Demonstrations

Mar 06, 2014, 14:47 ET from Misonix, Inc.

FARMINGDALE, N.Y., March 6, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently attended the 65th Southern Neurosurgical Society (SNS) Annual Meeting in San Juan, Puerto Rico from February 19-22, 2014.

Misonix exhibited and highlighted the BoneScalpel and SonaStar Ultrasonic Surgical Aspiration System. The Misonix BoneScalpel is a novel, ultrasonic surgical device that enables rapid, safe and precise osteotomies. It is designed to provide clean cuts through osseous structures with minimal loss of viable bone and intra-operative bleeding reduced, keeping the surgical site clear of blood. Reductions in operating room time can also be significant.  SonaStar offers precise and soft tissue aspiration and effective removal of osseous structures.  SonaStar state-of-the-art technology includes the most powerful handpiece on the market today, and wireless technology.  The Southern Neurosurgical Society is one of the largest regional neurosurgical societies with more than 300 active members from 17 states including Florida, North Carolina and Texas. This year's SNS Annual Meeting in San Juan attracted a record number of surgeon attendees who, over the course of the three-day meeting, had an opportunity to stop by the Misonix booth to trial the BoneScalpel and SonaStar systems.

Peyman Pakzaban, MD, FAANS from Houston MicroNeurosurgery in Houston, Texas, has stated, "As a neurosurgeon specializing in spinal microsurgery, I have had extensive experience with the use of BoneScalpel in spine surgery. The reduced risk of cerebrospinal fluid leak and neurological injury is expected to have significant economic benefits, such as reduced use of tissue sealants, diminished length of hospital stay and reduced rate of readmissions and reoperations for CSF complications. I believe BoneScalpel is as significant to spine surgery today as the adoption of the pneumatic drill was several decades ago."

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, "Our presence at the SNS furthers our commitment to introduce our novel, ultrasonic technology to some of the foremost neurosurgeons in the world.  We are very excited about the interest that the participating surgeons expressed in having the BoneScalpel and SonaStar evaluated at their respective institutions."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact:

Investor Contact:

Richard Zaremba

Joe Diaz


Lytham Partners




SOURCE Misonix, Inc.